Fortitude Family Office’s Edgewise Therapeutics EWTX Stock Holding History

Fortitude Family Office’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.2K	Buy	202 +42	+26%	+$1.78K	﹤0.01%	1314
2026 Q2	$6.5K	Hold	160	–	–	﹤0.01%	960
2026 Q1	$5.04K	Hold	160	–	–	﹤0.01%	906
2025 Q4	$3.97K	Hold	160	–	–	﹤0.01%	903
2025 Q3	$2.6K	Hold	160	–	–	﹤0.01%	1105
2025 Q2	$2.1K	Hold	160	–	–	﹤0.01%	1175
2025 Q1	$3.52K	Hold	160	–	–	﹤0.01%	817
2024 Q4	$4.27K	Hold	160	–	–	﹤0.01%	889
2024 Q3	$4.27K	Hold	160	–	–	﹤0.01%	832
2024 Q2	$2.88K	Hold	160	–	–	﹤0.01%	737
2024 Q1	$2.92K	Hold	160	–	–	﹤0.01%	754
2023 Q4	$1.75K	Buy	+160	New	+$1.12K	﹤0.01%	890

Other funds holding EWTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GIA

GHP Investment Advisors Denver, Colorado $2.68B AUM 19.3% 1-Year Est. Return

Fortitude Family Office's EWTX Position: Q3 2026 in Review

Fortitude Family Office increased its Edgewise Therapeutics (EWTX) stake by 26% in Q3 2026, buying an estimated $1.78K and bringing the position to 202 shares worth $8.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Fortitude Family Office first reported a position in EWTX in Q4 2023 and has held it in 12 quarters since. 9 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

Fortitude Family Office held 202 shares of Edgewise Therapeutics worth $8.2K as of Q3 2026.
Fortitude Family Office bought 42 Edgewise Therapeutics shares in Q3 2026, an estimated $1.78K.
Edgewise Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1314 holding.
Fortitude Family Office first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 12 quarters since.
9 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.